In a complaint filed in federal court, the U.S. Department of Justice claims NewYork-Presbyterian Hospital uses its power of “scale, breadth and configuration” to control payer contracts, making it difficult for insurers to develop low-cost plans. The health system denies any wrongdoing.

Led by a Quebec-based faith organization, a coalition of investors is asking a court to force UnitedHealth to provide details on the social impacts of its history of mergers and acquisitions. The lawsuit comes after the plaintiffs, all company shareholders, failed to get the proposal passed through internal channels. The Securities and Exchange Commission has also opted not to intervene. 

In a lawsuit seeking class action status, a woman identified as “P.M.” said she began using the website for Kisqali, a Novartis breast cancer treatment, in late 2024 shortly after being issued a prescription. Unbeknownst to her, sensitive data she shared when seeking a discount may have been shared with advertisers.

ImmunityBio, the developer of bladder cancer treatment Anktiva, is accused by the U.S. Food and Drug Administration of disseminating “false or misleading information” about the drug's efficacy in an advertisement and podcast. The FDA said it’s not the first time it's sent a warning letter to the company’s executives over allegedly inaccurate claims.

The new approach allows private practices to expand and evolve without being acquired.

San Diego-based Turquoise Health was founded in 2020 and has evolved to be a healthcare pricing engine used to develop health plan networks and contract rates. The company said its end goal is complete price transparency to make it easier for all organizations and patients to navigate the U.S. healthcare system.

The two not-for-profit health systems announced the merger on Wednesday. Although the deal won’t be finalized for some time, they teased new investments that will bring 39 hospitals and more than 400 primary and specialty care sites under the banner of a new Sutter Health. 

The problem is limited to surgical stapler reloads used by the da Vinci robot, specifically those manufactured by Intuitive Surgical. The FDA said it’s currently investigating why the reloads are leaving incomplete line formations. For now, they need to be pulled from all patient care settings.